Dergiler / Journal of Clinical Research in Pediatric Endocrinology / 2019 / Cilt: 11 - Sayı: 2

Management of Thyrotoxicosis in Children and Adolescents: A Turkish Multi-center Experience

Sayfa
164–172
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: This study has demonstrated that using ATDs is the generally accepted first-line approach and there seems to be low remission rate with ATDs in pediatric GD patients in Turkey.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To determine the demographic and biochemical features of childhood and juvenile thyrotoxicosis and treatment outcome.
📊
Temel Bulgular & Veri:Methods: We reviewed the records of children from 22 centers in Turkey who were diagnosed with thyrotoxicosis between 2007 to 2017.
💡
Sonuç & Katkı:Conclusion: This study has demonstrated that using ATDs is the generally accepted first-line approach and there seems to be low remission rate with ATDs in pediatric GD patients in Turkey.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2007 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: To determine the demographic and biochemical features of childhood and juvenile thyrotoxicosis and treatment outcome. Methods: We reviewed the records of children from 22 centers in Turkey who were diagnosed with thyrotoxicosis between 2007 to 2017. Results: A total of 503 children had been diagnosed with thyrotoxicosis at the centers during the study period. Of these, 375 (74.6%) had been diagnosed with Graves’ disease (GD), 75 (14.9%) with hashitoxicosis and 53 (10.5%) with other less common causes of thyrotoxicosis. The most common presenting features in children with GD or hashitoxicosis were tachycardia and/or palpitations, weight loss and excessive sweating. The cumulative remission rate was 17.6% in 370 patients with GD who had received anti-thyroid drugs (ATDs) for initial treatment. The median (range) treatment period was 22.8 (0.3-127) months. No variables predictive of achieving remission were identified. Twenty-seven received second-line treatment because of poor disease control and/or adverse events associated with ATDs. Total thyroidectomy was performed in 17 patients with no recurrence of thyrotoxicosis and all became hypothyroid. Ten patients received radioiodine and six became hypothyroid, one remained hyperthyroid and restarted ATDs and one patient achieved remission. Two patients were lost to follow up. Conclusion: This study has demonstrated that using ATDs is the generally accepted first-line approach and there seems to be low remission rate with ATDs in pediatric GD patients in Turkey.

🔖

Bu Makaleye Atıf Yap

ESEN, İ., BAYRAMOĞLU, E., YILDIZ, M., AYDIN, M., ÖZTURHAN, E., AYCAN, Z., BOLU, S., ÖNAL, H., KÖR, Y., ÖKDEMİR, D., ÜNAL, E., ÖNDER, A., EVLİYAOĞLU, O., ÇAYIR, A., TAŞTAN, M., YÜKSEL, A., KILINÇ, A., BÜYÜKİNAN, M., ÖZCABI, B., AKIN, O., BİNAY, Ç., KILINÇ, S., YILDIRIM, R. (2019). Management of Thyrotoxicosis in Children and Adolescents: A Turkish Multi-center Experience. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 11 - Sayı: 2, 164–172. https://ajindex.com/articles/190717

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016
  2. Epub 2016 Mar 30 2. Srinivasan S, Misra M. Hyperthyroidism in children. Pediatr Rev 2015
  3. Forssberg M, Arvidsson CG, Engvall J, Lindblad C, Snellman K, Aman J. Increasing incidence of childhood thyrotoxicosis in a population-based area of central Sweden. Acta Paediatr 2004
  4. Wong GW, Cheng PS. Increasing incidence of childhood Graves’ disease in Hong Kong: a follow-up study. Clin Endocrinol (Oxf) 2001
  5. Kumorowicz-Kopiec M, Dziatkowiak H, Starzyk J, Nizankowska-Błaz T, Rybakowa M. [Incidence of Graves disease in children in some regions of south-eastern Poland]. Przegl Lek 2004
  6. Havgaard Kjaer R, Smedegard Andersen M, Hansen D. Increasing Incidence of Juvenile Thyrotoxicosis in Denmark: A Nationwide Study, 1998-2012. Horm Res Paediatr 2015
  7. Epub 2015 Jun 24 7. Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Suzuki M, Yoshihara A, Ito K, Ito K. Antithyroid drug treatment for graves’ disease in children: a long-term retrospective study at a single institution. Thyroid 2014
  8. Epub 2013 Nov 13 8. Committee on Pharmaceutical Affairs, Japanese Society for Pediatric Endocrinology, and the Pediatric Thyroid Disease Committee, Japan Thyroid Association (Taskforce for the Revision of the Guidelines for the Treatment of Childhood-Onset Graves’ Disease), Minamitani K, Sato H, Ohye H, Harada S, Arisaka O. Guidelines for the treatment of childhood-onset Graves’ disease in Japan, 2016. Clin Pediatr Endocrinol 2017
  9. Epub 2017 Apr 22 9. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016
  10. Okawa ER, Grant FD, Smith JR. Pediatric Graves’ disease: decisions regarding therapy. Curr Opin Pediatr 2015
  11. Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015
  12. Epub 2014 Dec 15 12. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’